|
| 38008099 | Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. | Lancet Infect Dis | 2024 |
| 33558295 | Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: Results from a Spanish multicenter cohort. | Antimicrob Agents Chemother | 2023 |
| 37888093 | Clinical, Microbiological and Treatment Characteristics of Severe Postoperative Respiratory Infections: An Observational Cohort Study. | J Pers Med | 2023 |
| 37838452 | Multidrug-resistant Pseudomonas aeruginosa: A pathogen with challenging clinical management. | Enferm Infecc Microbiol Clin (Engl Ed) | 2023 |
| 37943035 | Colistin plasma concentrations are not associated with better clinical outcomes in patients with pneumonia caused by extremely drug-resistant <i>Pseudomonas aeruginosa</i>. | Microbiol Spectr | 2023 |
| 37541529 | Reducing the duration of antibiotic therapy in surgical patients through a specific nationwide antimicrobial stewardship program. A prospective, interventional cohort study. | Int J Antimicrob Agents | 2023 |
| 37823445 | Real-world experience of therapeutic drug monitoring and PK/PD achievement of ceftaroline administered by different infusion regimens in patients with confirmed infections caused by Gram-positive bacteria. | J Antimicrob Chemother | 2023 |
| 37727767 | <i>In vitro</i>, <i>in vivo</i> and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant <i>Enterobacterales</i> and multidrug-resistant <i>Pseudomonas aeruginosa</i> isolates or infections: a scoping review. | Front Med (Lausanne) | 2023 |
| 38034998 | A retrospective case-control study to evaluate the use of beta-lactam desensitization in the management of penicillin-allergic patients: a potential strategy for Antimicrobial Stewardship Programs. | Front Pharmacol | 2023 |
| 37726843 | Staphylococcus aureus surgical site infection rates in 5 European countries. | Antimicrob Resist Infect Control | 2023 |
| 37533351 | Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project). | J Antimicrob Chemother | 2023 |
| 37373850 | Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19. | J Clin Med | 2023 |
| 37294450 | Ampicillin-resistant and vancomycin-susceptible <i>Enterococcus faecium</i> bacteremia: a clinical narrative review. | Expert Rev Anti Infect Ther | 2023 |
| 36626402 | Pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections. | J Antimicrob Chemother | 2023 |
| 36653401 | Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients. | Sci Rep | 2023 |
| 36610836 | Antimicrobial stewardship in hospitals: Expert recommendation guidance document for activities in specific populations, syndromes and other aspects (PROA-2) from SEIMC, SEFH, SEMPSPGS, SEMICYUC and SEIP. | Enferm Infecc Microbiol Clin (Engl Ed) | 2023 |
| 36510684 | Antimicrobial resistance in Gram-negative bacilli in Spain: an experts' view. | Rev Esp Quimioter | 2023 |
| 34328373 | Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review. | Expert Rev Anti Infect Ther | 2022 |
| 35442442 | Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption. | Clin Infect Dis | 2022 |
| 35838033 | A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia. | Expert Rev Clin Pharmacol | 2022 |
| 35345821 | Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. | Clin Epidemiol | 2022 |
| 35695526 | Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates. | Microbiol Spectr | 2022 |
| 36069242 | Antibiotic desensitization as a potential tool in antimicrobial stewardship programs: retrospective data analysis and systematic literature review. | Expert Rev Anti Infect Ther | 2022 |
| 36358110 | Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence. | Antibiotics (Basel) | 2022 |
| 35876574 | ATP Bioluminescence Assay To Evaluate Antibiotic Combinations against Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa. | Microbiol Spectr | 2022 |
| 34860333 | Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort Study. | Infect Dis Ther | 2022 |
| 35336064 | A Descriptive Analysis of Urinary ESBL-Producing-<i>Escherichia coli</i> in Cerdanya Hospital. | Microorganisms | 2022 |
| 32955088 | Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. | Clin Infect Dis | 2021 |
| 33573070 | Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. | Antibiotics (Basel) | 2021 |
| 33572045 | Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. | Nutrients | 2021 |
| 33820765 | Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity. | Antimicrob Agents Chemother | 2021 |
| 33867313 | Epigenome-wide association study of COVID-19 severity with respiratory failure. | EBioMedicine | 2021 |
| 33618513 | Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study. | Rev Esp Quimioter | 2021 |
| 33639115 | Hospital-at-Home Expands Hospital Capacity During COVID-19 Pandemic. | J Am Med Dir Assoc | 2021 |
| 33658808 | Osteoarticular Cryptococcosis Successfully Treated with High-Dose Liposomal Amphotericin B Followed by Oral Fluconazole. | Infect Drug Resist | 2021 |
| 33553204 | Effects of Environmental Factors on Severity and Mortality of COVID-19. | Front Med (Lausanne) | 2021 |
| 33688639 | Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. | Res Sq | 2021 |
| 35106315 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. | Open Forum Infect Dis | 2021 |
| 34615586 | Clinical experience of TB in patients treated with anti-TNF-α. | Int J Tuberc Lung Dis | 2021 |
| 34491967 | Impact and Management of COVID-19 Among Healthcare Workers in Two Acute Care Hospitals and Two Associated Long-term Care Centres in Barcelona, Spain. | J Occup Environ Med | 2021 |
| 34756636 | Corrigendum to "Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study" [International Journal of Antimicrobial Agents, Volume 54, Issue 5 (2019) 572-578]. | Int J Antimicrob Agents | 2021 |
| 34773066 | Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. | Sci Rep | 2021 |
| 34504693 | SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B-cell responses. | Clin Transl Immunology | 2021 |
| 34827234 | Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. | Antibiotics (Basel) | 2021 |
| 34069184 | Risk Factors for Amoxicillin-Clavulanate Resistance in Community-Onset Urinary Tract Infections Caused by <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i>: The Role of Prior Exposure to Fluoroquinolones. | Antibiotics (Basel) | 2021 |
| 34067391 | Impact of a Nosocomial COVID-19 Outbreak on a Non-COVID-19 Nephrology Ward during the First Wave of the Pandemic in Spain. | Antibiotics (Basel) | 2021 |
| 34063338 | Clinical and Economic Impact of Community-Onset Urinary Tract Infections Caused by ESBL-Producing <i>Klebsiella pneumoniae</i> Requiring Hospitalization in Spain: An Observational Cohort Study. | Antibiotics (Basel) | 2021 |
| 34319141 | Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. | Microbiol Spectr | 2021 |
| 34198646 | Daptomycin versus Glycopeptides for the Treatment of <i>Enterococcus faecium</i> Bacteraemia: A Cohort Study. | Antibiotics (Basel) | 2021 |
| 34167610 | Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers. | Infect Control Hosp Epidemiol | 2021 |